Study of Daclizumab in Patients With Chronic, Persistent Asthma

Facet Biotech

Status and phase: Completed; Phase 2

Conditions: Asthma

Treatments: Drug: Daclizumab

Study type: Interventional

Funder types: Industry

Identifiers

NCT00028288

DAC-1003

Details and patient eligibility

About

The purpose of the study is to evaluate an investigational medication to treat chronic persistent asthma. The research is being conducted at up to 22 clinical research sites in the US and is open to both men and women ages 18 to 70 years old. Participants in the study will have a number of visits to a research site over a 10-month period. All study-related care and medication is provided to qualified participants at no cost: this includes all visits, examinations and laboratory work.

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• History of asthma for 6 or more months
• History of chronic persistent asthma requiring daily high dose inhaled corticosteroid for 3 or more months prior to enrollment

Exclusion criteria

• Patients with 10 or more pack years of smoking history or smoking within 12 months of study enrollment
• No significant disease other than asthma

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind